Cardio Diagnostics Holdings, Inc. (CDIOW) Analyse boursière

Présentation de l'entreprise

Cardio Diagnostics Holdings, Inc., operating under the ticker CDIOW, is a specialized entity focused on the development and commercialization of epigenetics-based clinical tests designed to assess risk for cardiovascular disease. The company specifically markets the Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment clinical blood test that targets CHD events, including heart attacks, alongside other offerings like Precisio. Although specific sector and industry classifications are not currently listed in public filings, the firm operates within the biomedical technology landscape, utilizing advanced scientific methodologies to address critical health monitoring needs. The company's operational scale is defined by a market capitalization that is not publicly disclosed, a trailing twelve-month revenue of $14,825, and a workforce consisting of 15 employees. These financial and structural metrics indicate that Cardio Diagnostics Holdings, Inc. functions as a micro-cap or early-stage biotechnology enterprise, where limited revenue and a small headcount suggest the company is in a resource-constrained phase typical of firms focused on R&D and clinical validation rather than established commercial dominance.

Santé financière

The company reported revenue of $14,825 over the trailing twelve months, yet it recorded a net income of $-6,498,167, creating a significant disparity that reveals a highly aggressive cost structure dominated by research and development expenses or operational burn. The EBITDA for the same period stood at $-6,085,950, further highlighting the substantial cash outflows required to sustain current operations before non-cash charges are considered. Free cash flow is negative at $-3,809,743, indicating that the company is burning through its liquidity to fund its growth initiatives and lacks the immediate financial flexibility to generate positive cash flow from its existing business model. Margins reflect this financial reality, with a gross margin of 100.0% suggesting the cost of goods sold is negligible relative to revenue, while the operating margin is a staggering -41159.6% and the profit margin is 0.0%, both of which signal that operating expenses far exceed revenue generation capabilities. On the balance sheet, the company holds $5.11M in cash against total debt of $695,619, resulting in a debt-to-equity ratio of 9.97, which suggests a highly leveraged position relative to equity, though the cash balance provides a buffer against short-term obligations. The current ratio is reported at 9.79, indicating a very strong liquidity position where current assets significantly exceed current liabilities, providing ample coverage for short-term debts despite the negative profitability. However, the return on equity is -78.6% and the return on assets is -44.1%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently in terms of generating positive returns.

Évaluation de la valorisation

Valuation metrics such as the P/E Ratio (TTM) and Forward P/E are not available due to the company's lack of profitability, meaning standard earnings-based valuation models cannot be applied to assess the company's intrinsic value relative to its earnings. The price-to-book ratio is recorded at 0.00, which indicates that the market capitalization is effectively zero or that the book value is negligible compared to the stock price, suggesting the market does not assign a traditional premium over the company's net asset value. Alternative valuation metrics like the price-to-sales ratio and EV/EBITDA are also not available, implying that investors must rely on fundamental risk assessment and potential clinical trial success rather than traditional multiples to gauge the company's worth. Regarding trading ranges, the 52-week high is $0.02 and the 52-week low is $0.01; without a specific current share price provided in the facts, the relative position cannot be calculated, but the narrow spread between these levels demonstrates extreme price compression typical of micro-cap biotech stocks. The stock exhibits a beta of 2.66, which signifies that the share price is highly volatile and tends to fluctuate with much greater intensity than the broader market, exposing holders to significant risk during periods of market turbulence.

Growth & Income

Revenue growth year-over-year stands at -21.2%, while earnings growth is not applicable given the company's continued net losses, indicating that the company is shrinking in terms of top-line revenue generation while simultaneously incurring deep losses. Since the company is not a dividend payer, the dividend yield and payout ratio are not applicable, which means the firm does not distribute income to shareholders and instead retains all earnings to attempt to fund future operations or research. Consequently, the company reinvests its limited resources directly into its product pipeline and clinical development efforts rather than providing a yield to investors, a common strategy for pre-revenue or early-stage biotechnology companies seeking to achieve market validation. The overall growth and income profile is characterized by negative revenue expansion, substantial cash burn, and an absence of dividend income, reflecting a high-risk investment thesis centered on the potential future success of its cardiovascular testing platforms rather than current financial performance.